Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
FATE THERAPEUTICS INC (FATE)
Sector: Healthcare; Industry: Biotechnology

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-01-11 Wolchko J Scott President and CEO Sell 14,566 $48.68 $709,027 No
2022-01-11 TAHL CINDY General Counsel and Secretary Sell 5,419 $48.53 $262,975 No
2022-01-11 Valamehr Bahram Chief R&D Officer Sell 4,570 $48.50 $221,655 No
2022-01-11 Dulac Edward J III Chief Financial Officer Sell 1,770 $48.45 $85,757 No
2022-01-11 Chu Yu-Waye Senior VP Clinical Development Sell 3,965 $48.51 $192,340 No
2022-01-10 Wolchko J Scott President and CEO Sell 34,156 $46.86 $1,600,534 No
2022-01-10 TAHL CINDY General Counsel and Secretary Sell 7,738 $46.43 $359,313 No
2022-01-10 Valamehr Bahram Chief R&D Officer Sell 5,596 $46.38 $259,558 No
2022-01-03 TAHL CINDY General Counsel and Secretary Sell 50,000 $59.34 $2,966,853 Yes
2021-12-20 Dulac Edward J III Chief Financial Officer Sell 15,977 $60.00 $958,620 Yes
2021-12-13 Valamehr Bahram Chief R&D Officer Sell 25,000 $47.66 $1,191,406 Yes
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sell 7,500 $51.46 $385,948 Yes
2021-11-19 Wolchko J Scott President and CEO Sell 20,000 $54.27 $1,085,400 Yes
2021-10-22 Wolchko J Scott President and CEO Sell 60,000 $59.55 $3,572,960 Yes
2021-10-01 TAHL CINDY General Counsel and Secretary Sell 50,000 $58.83 $2,941,462 Yes
2021-09-28 Dulac Edward J III Chief Financial Officer Sell 19,460 $62.53 $1,216,834 Yes
2021-09-13 Valamehr Bahram Chief Development Officer Sell 25,000 $66.29 $1,657,257 Yes
2021-07-23 Wolchko J Scott President and CEO Sell 60,000 $85.67 $5,140,113 Yes
2021-06-14 Valamehr Bahram Chief Development Officer Sell 25,000 $89.32 $2,233,045 Yes
2021-05-20 Wolchko J Scott President and CEO Sell 20,000 $77.16 $1,543,292 Yes
2021-04-23 Wolchko J Scott President and CEO Sell 60,000 $85.39 $5,123,496 Yes
2021-04-16 Chu Yu-Waye Senior VP Clinical Development Sell 3,275 $83.30 $272,809 No
2021-04-01 TAHL CINDY nan Sell 30,000 $83.81 $2,514,329 Yes
2021-03-15 Valamehr Bahram Chief Development Officer Sell 25,000 $92.35 $2,308,772 Yes
2021-03-08 Shoemaker Daniel D Chief Scientific Officer Sell 25,000 $81.74 $2,043,428 No
2021-02-18 Wolchko J Scott President and CEO Sell 20,000 $102.01 $2,040,258 Yes
2021-01-22 Wolchko J Scott President and CEO Sell 60,000 $100.67 $6,039,968 Yes
2021-01-19 TAHL CINDY General Counsel and Secretary Sell 35,000 $114.76 $4,016,639 Yes
2021-01-11 Wolchko J Scott President and CEO Sell 69,407 $116.33 $8,073,772 No
2021-01-11 Valamehr Bahram Chief Development Officer Sell 9,484 $114.95 $1,090,140 No

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.